Wilson's Disease Drugs Global Market Report 2025

The wilson's disease drugs market size has grown strongly in recent years. It will grow from $0.62 billion in 2024 to $0.66 billion in 2025 at a compound annual growth rate (CAGR) of 6.8%. The historical growth can be linked to increased awareness about Wilson’s disease and its symptoms, expanded clinical research activities, broader access to standardized treatments, improvements in healthcare infrastructure, and a higher number of diagnosed patients.

The wilson's disease drugs market size is expected to see strong growth in the next few years. It will grow to $0.85 billion in 2029 at a compound annual growth rate (CAGR) of 6.5%. This projected growth is driven by higher investments in innovative drug research and gene therapy, a surge in personalized medicine practices, expansion of patient education initiatives, increased healthcare expenditure, and more regulatory approvals. Key trends expected during the forecast period include advancements in gene therapy, increased application of biomarkers to track disease development, integration of digital healthcare solutions, broader recognition through orphan drug status, rising investments, and the emergence of combination treatment strategies.

The rising incidence of genetic disorders is anticipated to drive the growth of the Wilson's disease drugs market. Genetic disorders result from abnormalities in an individual's DNA, including mutations, deletions, or chromosomal changes. The increase in genetic disorders is primarily attributed to higher parental age, which elevates the likelihood of inheritable mutations being passed to offspring. Wilson's disease drugs are used to treat this genetic condition by reducing harmful copper accumulation caused by ATP7B gene mutations. These drugs work by promoting copper excretion or inhibiting its absorption, thereby protecting vital organs such as the liver and brain. For example, according to the Cystic Fibrosis Trust, a UK-based national charity, in September 2023, the number of patients in the UK registered with cystic fibrosis rose to 11,148 in 2022, up from 10,908 in 2021. Consequently, the increasing prevalence of genetic disorders is supporting the expansion of the Wilson's disease drugs market.

Leading companies in the Wilson's disease drug market are developing advanced drug formulations, such as trientine tetrahydrochloride (TETA-4HCl), to improve treatment outcomes and enhance patient convenience in managing rare diseases. Trientine tetrahydrochloride (TETA-4HCl) is an advanced oral copper-chelating therapy tailored to maintain copper balance in adult patients with stable Wilson's disease. For instance, in April 2023, Orphalan SA, a France-based company specializing in orphan drug development and commercialization, introduced Cuvrior. Approved by the Food and Drug Administration (FDA) and granted Orphan Drug Exclusivity, Cuvrior is a new trientine tetrahydrochloride (TETA-4HCl) formulation designed for adults with stable Wilson's disease who are already decoppered and tolerant to penicillamine. It offers a room temperature-stable oral therapy that enhances dosing flexibility and convenience compared to earlier treatments.

In January 2025, Eton Pharmaceuticals, a US-based pharmaceutical company, acquired Galzin from Teva Pharmaceuticals USA for an undisclosed amount. This acquisition reflects Eton Pharmaceuticals’ dedication to rare disease treatments by adding an FDA-approved therapy for the ultra-rare metabolic condition Wilson's disease to its portfolio. Teva Pharmaceuticals USA, Inc. is a US-based pharmaceutical manufacturer of Wilson's disease drugs.

Major players in the wilson's disease drugs market are Pfizer Inc., Merck & Co. Inc., Sanofi S.A., AstraZeneca plc, Teva Pharmaceutical Industries Ltd., Bausch Health Companies Inc., Intas Pharmaceuticals Ltd., Sun Pharmaceutical Industries Ltd., Dr. Reddy’s Laboratories, Lupin Pharmaceuticals, Ultragenyx Pharmaceutical Inc., Taj Pharmaceutical Limited, Biophore Pharma Inc., Orphalan SA, Nobelpharma Co. Ltd, Eton Pharmaceuticals, LogicBio Therapeutics, DepYmed, Vivet Therapeutics, Telomir Pharmaceuticals Inc., and Innorna.

North America was the largest region in the wilson's disease drugs market in 2024. The regions covered in this report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the Wilson's Disease Drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Wilson’s disease drugs are treatments used to address a rare inherited disorder that causes excessive copper accumulation, primarily in the liver and brain. These medications function by either promoting the elimination of copper from the body or preventing its absorption. Their main goal is to avoid or reverse damage to organs, especially the liver and nervous system.

The key categories of Wilson’s disease drugs include chelating agents, zinc-based therapies, liver transplantation, and supportive symptom management. Chelating agents help manage Wilson’s disease by binding to surplus copper, allowing it to be excreted through urine, thereby quickly decreasing copper toxicity. These drugs are administered via oral, intravenous, and subcutaneous routes and are distributed through hospital pharmacies, retail outlets, online platforms, and other channels. They are utilized by various end-users, such as hospitals, home care providers, specialty clinics, and more.

The wilson’s disease drugs market research report is one of a series of new reports that provides wilson’s disease drugs market statistics, including the wilson’s disease drugs industry global market size, regional shares, competitors with the wilson’s disease drugs market share, detailed wilson’s disease drugs market segments, market trends, opportunities, and any further data you may need to thrive in the wilson’s disease drugs industry. This Wilson’s disease drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The wilson's disease drugs market consists of sales of zinc salts, penicillamine, and trientine. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.